ANI Pharmaceuticals Announced The Launch Of Pentoxifylline Extended-Release Tablets, USP 400 Mg
Portfolio Pulse from Benzinga Newsdesk
ANI Pharmaceuticals, Inc. has launched Pentoxifylline Extended-Release Tablets, USP 400 mg, a generic version of Trental. The U.S. market for this medication is estimated to be around $19.7 million annually, based on IQVIA/IMS Health data.

January 23, 2024 | 11:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ANI Pharmaceuticals has launched a generic version of Trental, which could capture a share of the $19.7 million annual U.S. market for Pentoxifylline ER Tablets.
The launch of a new generic drug by ANI Pharmaceuticals is likely to have a positive impact on the company's revenue, given the size of the existing market for the branded version. As the company captures market share, this could lead to increased sales and potentially a positive reaction in the stock price in the short term. The confidence in this analysis is high due to the specific mention of the market size and the direct relation of the product launch to ANI Pharmaceuticals' business.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100